Log In
Print
BCIQ
Print
Print this Print this
 

ALN-AT3

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionRNAi therapeutic targeting anti-thrombin III (AT3; SERPINC1) mRNA
Molecular Target Anti-thrombin III (AT3) (SERPINC1)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPhase I
Standard IndicationHemophilia
Indication DetailsTreat hemophilia; Treat hemophilia A; Treat hemophilia B
Regulatory Designation

U.S. - Orphan Drug (Treat hemophilia B);
U.S. - Orphan Drug (Treat hemophilia A);
EU - Orphan Drug (Treat hemophilia)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today